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Résumé en
anglais
Therapeutic failures attributed to medical management of cystic echinococcosis
(CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption
rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules
(LNCs) represent nanocarriers designed to encapsulate lipophilic drugs, such as
ABZ. The goals of the current work were: i) to characterize the plasma and cyst
drug exposure after the administration of ABZ as ABZ-LNCs or ABZ suspension
(ABZ-SUSP) in mice infected with Echinococcus granulosus, and ii) to compare the
clinical efficacies of both ABZ formulations. Enhanced ABZ sulphoxide (ABZ-SO)
concentration profiles were obtained in plasma and cysts from ABZ-LNC treated
animals. ABZSO exposure (AUC0-LOQ) was significantly higher in plasma and cyst
after the ABZ-LNC treatments, both orally and subcutaneously, compared to that
observed after oral administration of ABZ-SUSP. Additionally, ABZSO
concentrations measured in cysts from ABZ-LNC treated mice were 1.7-fold higher
than those detected in plasma. This enhanced drug availability correlated with an
increased efficacy against secondary CE in mice observed for the ABZ-LNCs, while
ABZ-SUSP did not reach differences with the untreated control group. This new
pharmacotechnically-based strategy could be a potential alternative to improve the
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